DALLAS/PRNewswire/ -- Eclipse MedCorp, a leading medical device company, has expanded its portfolio by acquiring worldwide control of a novel, autologous point-of-care technology in regenerative medicine. In the transaction, Eclipse obtains exclusive rights to the intellectual property (IP) and will jointly own additional IP as it is developed.
"This acquisition marks a tremendous moment for Eclipse as we seek best-in-class solutions to serve our physicians and their patients," said Tom O'Brien, CEO and Founder of Eclipse. "This significant technology will be rapidly commercialized in multiple fields of use on a worldwide basis. The acquisition will strengthen Eclipse's position as a global leader in regenerative medicine for years to come."
Dr. Sanjay Batra, President of Regenerative Medicine for Eclipse led the acquisition and introduced the technology to its Medical & Scientific Board at its annual meeting in Chicago on October 6, 2018.
The Eclipse Medical Advisory board is comprised of eminent dermatologists (Dr. Wilma Bergfeld, Dr. Neil Sadick and Dr. Jeffrey Rapaport) and plastic surgeons (Dr. Gordon Sasaki and Dr. Steven Dayan). Positive feedback was received by all members and Dr. Dayan noted that "this strategic move marks a major inflection point for Eclipse as it moves from being a distributor to an innovator, owner and manufacturer of world class medical technology."
CONTACT: Matt Longman, mlongman@eclipsemed.com
